Galileo is continually seeking strategic partners in support of its research strategy.
Galileo has initiated gene discovery programs in several major disease areas including psychiatric, neurological, cardiovascular, metabolic, dermatological, respiratory, gastrointestinal, ophthalmologic, and women’s health. Chromosomal candidate regions in many of these programs have been identified and are being narrowed to find disease genes.
Gene Discovery Alliances
Galileo would like to establish early-stage gene discovery alliances with strategic partners performing research and development in major disease areas. Such partners will receive access to Galileo’s disease program and exclusive rights for the development of diagnostic and therapeutic products for a minimal up-front fee.
Galileo is pursuing several disease gene discovery programs without alliance participation. Genes discovered through these programs will be licensed to pharmaceutical and biotechnology companies for diagnostic and therapeutic purposes.
Technology Development and other Partnerships
Galileo welcomes discussions with companies possessing complementary technologies such as DNA collection, DNA genotyping, biochemical pathway mapping, drug target identification, and proteomics.
For further information, please contact Dr. Gregory Feulner, Vice-President of Business Development.